Arvinas, Inc. (ARVN)
Arvinas, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Arvinas, Inc. (ARVN) is a Biotechnology company based in US with a market capitalization of $532.9M. Revenue declined 0.3% year-over-year and free cash flow was negative at -$275.7M. This page tracks ARVN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 430 employees · IPO Sep 27, 2018
Valuation
Valuation & price
$9.08as of May 17, 2026· -34.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.23
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$532.9M
Market cap
-0.3%
Revenue growth (YoY)
98.0%
Gross margin
-$275.7M
Free cash flow (USD)
-$676.5M
Net debt
Net cash position
-9.7%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 25, 2026Filing
Annual Meeting Results
- Insider sellJun 24, 2026Filing
Insider Sell $46KSaik Andrew · Chief Financial Officer · $46.5K
- 8-K eventJun 22, 2026Filing
CMO Departure
- 8-K eventJun 16, 2026Filing
License Agreement Effective
- 8-K eventJun 2, 2026Filing
Investor Presentation Scheduled
- 8-K eventMay 12, 2026Filing
License Agreement Signed
- 8-K eventMay 12, 2026Filing
Earnings Release
- Quarterly reportMay 11, 2026Filing
10-Q Filed
- 8-K eventMay 1, 2026Filing
FDA Approval
Questions
Frequently asked questions
What is Arvinas, Inc.'s market cap?
Arvinas, Inc. (ARVN) has a market capitalization of $532.9M.
What is ARVN's P/E ratio?
A meaningful P/E ratio is not available for ARVN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ARVN's price-to-book (P/B) ratio?
ARVN trades at 1.23 times book value per share.
Are insiders buying ARVN stock?
SEC Form 4 filings show no open-market insider buys at Arvinas, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.